Catalent Pharma Solutions has expanded its capabilities to include a new potent products area at its Schorndorf site in Germany. The company can now provide complex dose form production, overencapsulation and packaging solutions for potent products at its Schorndorf site.

Catalent’s Schorndorf operation provides a range of services to global, regional and local pharmaceutical customers. The Schorndorf facility successfully completed an FDA inspection in the fall of 2009.

“We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our customers, both global and local. I am also pleased that this investment was made here in Schorndorf, as it builds upon our team’s commitment to operational excellence, our regulatory track record, and our consistent focus on meeting our customers’ needs,” said Eric Schmidhaeuser, managing director of the Schorndorf operation.

Click here for more information about Catalent